Reference: 1162 Title: Metformin Lowers Cancer Risk via AMPK Activation Summary: Diabetic patients on metformin may see a 30–50% reduction in cancer risk due to the drug's activation of AMPK, which inhibits cancer cell growth. URL: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00617/full